JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Panzegrau, B.
Right arrow Articles by Goudy, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panzegrau, B.
Right arrow Articles by Goudy, G. H.
Journal of Nuclear Medicine Technology Volume 33, Number 1, 2005 28-30
© 2005 by Society of Nuclear Medicine

Outpatient Therapeutic 131I for Thyroid Cancer

Beata Panzegrau, MD;1, Leonie Gordon, MD;1 and Glen H. Goudy2

1Department of Radiology, Medical University of South Carolina, Charleston, South Carolina;
2Department of Radiation Safety, Medical University of South Carolina, Charleston, South Carolina

Objective:

We retrospectively analyzed the safety, cost effectiveness, and patient acceptance of outpatient high-dose 131I treatment for thyroid cancer at our hospital since 1997, when the Nuclear Regulatory Commission began allowing high-dose outpatient therapy with radioiodine.

Methods:

Forty-eight patients were treated as outpatients because their living conditions were acceptable and they were willing to comply with radiation safety guidelines. The homes of 3 patients were surveyed for contamination. The cost of outpatient treatment was compared with the cost of inpatient treatment. Patient acceptance was assessed by patient satisfaction surveys performed at the time of the posttherapy scan.

Results:

No levels of contamination above regulatory levels were found in patients’ homes. The cost of outpatient treatment was favorable. All surveyed patients were pleased with the procedure.

Conclusion:

If state and federal guidelines for releasing patients are followed, and if patients’ living conditions are adequately assessed, outpatient treatment with high-dose 131I is safe and cost effective and improves patient satisfaction.

Key Words: thyroid cancer; 131I treatment; outpatient






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2005 by the Society of Nuclear Medicine Technologist Section.